SPAG5 (Sperm-associated antigen 5), also known as SPATA5 or Map126. is a protein encoded by the SPAG5 gene located on human chromosome 17q11.2. Initially identified for its role in spermatogenesis, SPAG5 has gained attention for its critical involvement in mitotic regulation, particularly in spindle assembly, chromosome alignment, and cell cycle progression through the G2/M phase. It interacts with microtubule-associated proteins and components of the chromosomal passenger complex, ensuring proper mitotic fidelity.
In cancer biology, SPAG5 is frequently overexpressed in malignancies such as breast, ovarian, and hepatocellular carcinomas. Its upregulation correlates with aggressive tumor behavior, including enhanced proliferation, metastasis, and resistance to apoptosis. Studies suggest SPAG5 may serve as a prognostic biomarker, with elevated expression linked to poorer clinical outcomes and chemotherapy resistance. This has spurred interest in targeting SPAG5 for therapeutic interventions, though specific mechanisms remain under investigation.
SPAG5 antibodies are essential tools for detecting and quantifying the protein in research and diagnostic contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study SPAG5's spatial-temporal expression, cellular localization, and interaction partners. Commercially available antibodies vary in specificity, with validation data crucial for ensuring reliability. Recent studies also explore SPAG5’s potential as a predictive biomarker for patient stratification in therapies targeting mitotic vulnerabilities or immune checkpoint pathways.